Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIH PROPOSED CRADA CONFLICT-OF-INTEREST POLICY

Executive Summary

NIH PROPOSED CRADA CONFLICT-OF-INTEREST POLICY will adversely affect the ability of a company to complete commercial development of a National Institutes of Health invention, Association of Biotechnology Companies Exec VP Bruce Mackler (D.C. law firm Mackler, Cooper and Gibbs) told the association's annual meeting in Washington March 29. The proposed NIH policy would require a one-year hiatus between an NIH researcher's involvement in a CRADA (cooperative research and development agreement) and that researcher's employment with a sponsoring firm on a consulting basis. During Q&A following a presentation by NIH Director James Wyngaarden, Mackler asserted that the proposed policy will prevent companies from getting a researcher's assistance in solving such problems as process design and quality control, which contract R&D agreements do not typically cover. "I think NIH has to be sensitive to that -- if they want, under the Technology Transfer Act, to transfer the technology -- implementing into a manufacturing process is also part of the transfer," Mackler said. Responding, Wyngarden said NIH will consider the issue in developing its conflict-of-interest policies. "I don't know the answer," he said, "but I take the point." ABC outlined its position on CRADAs in a March 22 letter to NIH Office of Invention Development Director Reid Adler. The letter suggests that a "better approach" to the one-year CRADA/consulting hiatus plan would be "documentation of the circumstances surrounding both, with approval procedures, and not allowing them to occur simultaneously." The proposed "restrictions on CRADAs and consulting undercut NIH's interest in allowing the public to benefit rapidly from its work and its interest in collecting royalties on behalf of the federal government and NIH inventors," the letter states. "Further," the letter adds, "it seems innappropriate to work with a company toward commercial development of a product and then require the NIH personnel involved to abandon the company during one of the most difficult and expensive stages of commercial development."
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS015349

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel